Analyst Roy Buchanan of JMP Securities reiterated a Buy rating on CureVac (CVAC – Research Report), retaining the price target of $16.00.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback